Literature DB >> 32568509

Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles.

Hetika D Vora1, Mai Johnson1, Roberto J Brea1, Andrew K Rudd1, Neal K Devaraj1.   

Abstract

Activating mutations in the small GTPase NRAS are responsible for driving tumor growth in several cancers. Unfortunately, the development of NRAS inhibitors has proven difficult due to the lack of hydrophobic binding pockets on the protein's surface. To overcome this limitation, we chose to target the post-translational S-palmitoyl modification of NRAS, which is required for its signaling activity. Utilizing an amphiphile-mediated depalmitoylation (AMD) strategy, we demonstrate the ability to directly cleave S-palmitoyl groups from NRAS and inhibit its function. C8 alkyl cysteine causes a dose-dependent decrease in NRAS palmitoylation and inhibits downstream signaling in melanoma cells with an activating mutation in NRAS. This compound reduces cell growth in NRAS-driven versus non-NRAS-driven melanoma lines and inhibits tumor progression in an NRAS-mutated melanoma xenograft mouse model. Our work demonstrates that AMD can effectively suppress NRAS activity and could represent a promising new avenue for discovering lead compounds for treatment of NRAS-driven cancers.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32568509      PMCID: PMC7556697          DOI: 10.1021/acschembio.0c00222

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  41 in total

1.  A live cell, image-based approach to understanding the enzymology and pharmacology of 2-bromopalmitate and palmitoylation.

Authors:  Ivana Mikic; Sonia Planey; Jun Zhang; Carolina Ceballos; Terri Seron; Benedikt von Massenbach; Rachael Watson; Scott Callaway; Patrick M McDonough; Jeffrey H Price; Edward Hunter; David Zacharias
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

2.  Site-specific analysis of protein S-acylation by resin-assisted capture.

Authors:  Michael T Forrester; Douglas T Hess; J Will Thompson; Rainbo Hultman; M Arthur Moseley; Jonathan S Stamler; Patrick J Casey
Journal:  J Lipid Res       Date:  2010-11-02       Impact factor: 5.922

3.  Palmitoylation of oncogenic NRAS is essential for leukemogenesis.

Authors:  Benjamin Cuiffo; Ruibao Ren
Journal:  Blood       Date:  2010-03-03       Impact factor: 22.113

Review 4.  Drugging RAS: Know the enemy.

Authors:  Bjoern Papke; Channing J Der
Journal:  Science       Date:  2017-03-16       Impact factor: 47.728

Review 5.  Targeting protein lipidation in disease.

Authors:  Marilyn D Resh
Journal:  Trends Mol Med       Date:  2012-02-17       Impact factor: 11.951

Review 6.  Regulating the regulator: post-translational modification of RAS.

Authors:  Ian M Ahearn; Kevin Haigis; Dafna Bar-Sagi; Mark R Philips
Journal:  Nat Rev Mol Cell Biol       Date:  2011-12-22       Impact factor: 94.444

7.  MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.

Authors:  Kyle Crassini; Yandong Shen; William S Stevenson; Richard Christopherson; Chris Ward; Stephen P Mulligan; O Giles Best
Journal:  Br J Haematol       Date:  2018-05-16       Impact factor: 6.998

8.  CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.

Authors:  Rehana L Ahmed; Daniel P Shaughnessy; Todd P Knutson; Rachel I Vogel; Khalil Ahmed; Betsy T Kren; Janeen H Trembley
Journal:  Pharmaceuticals (Basel)       Date:  2019-04-02

9.  Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis.

Authors:  Hao-Hsuan Jeng; Laura J Taylor; Dafna Bar-Sagi
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

10.  Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).

Authors:  Thomas F Gajewski; April K S Salama; Donna Niedzwiecki; Jeffrey Johnson; Gerald Linette; Cynthia Bucher; Michelle A Blaskovich; Said M Sebti; Frank Haluska
Journal:  J Transl Med       Date:  2012-12-10       Impact factor: 5.531

View more
  1 in total

1.  Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Authors:  Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-08-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.